Cargando…

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure

AIMS: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre‐specified subgroup analysis in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossignol, Patrick, Williams, Bryan, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Ackourey, Gail, White, William B., Agarwal, Rajiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2020
Materias:	TREATMENT
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540031/ https://www.ncbi.nlm.nih.gov/pubmed/32452085 http://dx.doi.org/10.1002/ejhf.1860

Ejemplares similares

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
por: Reinisch, Walter, et al.
Publicado: (2023)

Suprascapular nerve block for the treatment of adhesive capsulitis: a randomised double-blind placebo-controlled trial
por: Shanahan, E Michael, et al.
Publicado: (2022)

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies
por: van den Brink, Wim, et al.
Publicado: (2013)

A double‐blind, placebo‐controlled trial on the antihypertensive treatment effect of a quadruple single‐pill combination
por: Hu, Lei‐Xiao, et al.
Publicado: (2021)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
por: Parthasarathy, Hari K., et al.
Publicado: (2009)

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
por: Anker, Stefan D., et al.
Publicado: (2015)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis
por: Motta, Luis Souza, et al.
Publicado: (2023)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant
por: Schnelle, Kendra, et al.
Publicado: (2020)

Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
por: Makhlough, Atieh, et al.
Publicado: (2014)

Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD
por: Mårup, Frederik Husum, et al.
Publicado: (2022)

Development of a Psychologically Enhanced Interactive Online Intervention for Hazardous Drinking
por: Linke, Stuart, et al.
Publicado: (2008)

Intervention against Excessive Alcohol Consumption in Primary Health Care: A Survey of GPs' Attitudes and Practices in England 10 Years On
por: Wilson, Graeme B., et al.
Publicado: (2011)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial
por: Düngen, Hans-Dirk, et al.
Publicado: (2011)

Early Treatment for Women with Alcohol Addiction (EWA) Reduces Mortality: A Randomized Controlled Trial with Long-Term Register Follow-up
por: Gjestad, Rolf, et al.
Publicado: (2011)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial
por: Siminiak, Tomasz, et al.
Publicado: (2012)

Awareness and Treatment of Alcohol Dependence in Japan: Results from Internet-Based Surveys in Persons, Family, Physicians and Society
por: Taguchi, Yurie, et al.
Publicado: (2014)

The Alcohol Improvement Programme: Evaluation of an Initiative to Address Alcohol-Related Health Harm in England
por: Thom, Betsy, et al.
Publicado: (2013)

Nine-year follow-up of local implantation of autologous skeletal myoblasts in a patient with coronary heart disease
por: Zhang, Dingguo, et al.
Publicado: (2013)

Treating neglected tropical diseases
por: Hopkins, Adrian
Publicado: (2013)

The Impact of Brief Alcohol Interventions in Primary Healthcare: A Systematic Review of Reviews
por: O'Donnell, Amy, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v09d9ac2knrnd0in6oc2dql89t